Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
4-epidoxorubicin + 5-fluorouracil + cyclophosphamide + interferon-β + prednisone + retinyl palmitate + tamoxifen + vincristine
- Development stage
- Preclinical
- Lead developer
- Takeda
- Modality
- Small Molecules
- Administration
- Intravenous, Oral, Intramuscular, Subcutaneous
01
Overview
This is a combination chemotherapy regimen containing multiple agents with different mechanisms of action. 4-epidoxorubicin (epirubicin) is an anthracycline that exerts antitumor effects by interfering with DNA synthesis and function. It inhibits topoisomerase II activity and DNA helicase activity, preventing DNA replication and transcription. Interferon-β is an immunomodulator that helps regulate immune response. The combination likely targets various cancer types, particularly breast cancer, as several components (epirubicin, cyclophosphamide, and tamoxifen) are commonly used in breast cancer treatment.
- Other names
- epirubicin + 5-fluorouracil + cyclophosphamide + interferon-β + prednisone + retinyl palmitate + tamoxifen + vincristine
02
Targets
TS (Thymidylate synthase)GR (Glucocorticoid receptor)DNATUBB (Tubulin (alpha and beta subunits))RARA (Retinoic acid receptor alpha)TOP2A (DNA topoisomerase II)ESR1 (ERα)
Beyond the preview
Go deeper on 4-epidoxorubicin + 5-fluorouracil + cyclophosphamide + interferon-β + prednisone + retinyl palmitate + tamoxifen + vincristine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 4-epidoxorubicin + 5-fluorouracil + cyclophosphamide + interferon-β + prednisone + retinyl palmitate + tamoxifen + vincristine.